Neuroscience and technology firm electroCore has commercially launched its non-invasive vagus nerve stimulator gammaCore in the US, to acutely treat pain associated with episodic cluster headache in adults.

The hand-held medical device can be applied to the neck to send mild electrical stimulation through the skin for stimulation of afferent fibres of the vagus nerve that in turn causes mitigation of the pain.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

gammaCore is a portable, easy-to-use technology, which can be self-administered without potential side effects that are usually observed during standard of care.

electroCore CEO Francis Amato said: “It provides episodic cluster headache sufferers with a much-needed treatment option for this rare and often debilitating condition.

“The commercial launch also signifies an important milestone for electroCore, marking the first marketed product for the company in the US.”

"It provides episodic cluster headache sufferers with a much-needed treatment option for this rare and often debilitating condition."

The US Food and Drug Administration (FDA) released the vagus nerve stimulator in April and granted 510(k) clearance for commercialisation in the country in June.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

gammaCore is accessible to the patients who are enrolled in a non-research registry called gammaCore Patient Registry (GPR) established at select headache centres in the country to assess patient experience with the device.

The registered patients will be eligible to receive gammaCore treatment over a period of two months at free of cost and are required to share their experience, as well as information on periodic quality-of-life and self-reported outcomes.

GPR additionally offers an online tracker to record cluster attacks, training from a GPR coordinator on gammaCore use, and access to support from a care specialist during the treatment period.

Image: gammaCore. Photo: courtesy of PRNewsfoto/electroCore LLC.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact